Oramed Pharmaceuticals (ORMP) Competitors $2.32 -0.04 (-1.86%) As of 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. RVNC, ABVX, HUMA, AURA, RAPP, RNAC, TSHA, ATXS, HRTX, and BNTCShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Revance Therapeutics (RVNC), ABIVAX Société Anonyme (ABVX), Humacyte (HUMA), Aura Biosciences (AURA), Rapport Therapeutics (RAPP), Cartesian Therapeutics (RNAC), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), Heron Therapeutics (HRTX), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Revance Therapeutics ABIVAX Société Anonyme Humacyte Aura Biosciences Rapport Therapeutics Cartesian Therapeutics Taysha Gene Therapies Astria Therapeutics Heron Therapeutics Benitec Biopharma Revance Therapeutics (NASDAQ:RVNC) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment. Is RVNC or ORMP more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Revance Therapeutics-74.67% N/A -37.22% Oramed Pharmaceuticals N/A -7.27%-6.20% Which has more risk and volatility, RVNC or ORMP? Revance Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Which has stronger valuation & earnings, RVNC or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevance Therapeutics$234.04M1.63-$323.99M-$1.93-1.89Oramed Pharmaceuticals$1.34M69.67$5.53M$0.1121.05 Does the MarketBeat Community believe in RVNC or ORMP? Revance Therapeutics received 82 more outperform votes than Oramed Pharmaceuticals when rated by MarketBeat users. However, 72.50% of users gave Oramed Pharmaceuticals an outperform vote while only 60.03% of users gave Revance Therapeutics an outperform vote. CompanyUnderperformOutperformRevance TherapeuticsOutperform Votes40160.03% Underperform Votes26739.97% Oramed PharmaceuticalsOutperform Votes31972.50% Underperform Votes12127.50% Do analysts prefer RVNC or ORMP? Revance Therapeutics presently has a consensus price target of $8.39, indicating a potential upside of 129.75%. Given Revance Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Revance Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revance Therapeutics 0 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.11Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer RVNC or ORMP? In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Revance Therapeutics. MarketBeat recorded 3 mentions for Oramed Pharmaceuticals and 1 mentions for Revance Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 0.87 beat Revance Therapeutics' score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revance Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in RVNC or ORMP? 97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryOramed Pharmaceuticals beats Revance Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.48M$6.91B$5.63B$8.10BDividend YieldN/A2.73%4.56%4.02%P/E Ratio21.087.2224.5519.02Price / Sales69.67225.58383.6492.49Price / CashN/A65.6738.1634.64Price / Book0.576.506.954.34Net Income$5.53M$142.41M$3.20B$247.23M7 Day Performance-2.28%-3.10%-2.42%-0.71%1 Month Performance10.29%-4.64%2.96%-3.92%1 Year Performance-17.87%-8.32%11.14%1.61% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.4922 of 5 stars$2.32-1.9%N/A-13.2%$93.48M$1.34M21.0810Positive NewsRVNCRevance Therapeutics2.0247 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastABVXABIVAX Société Anonyme2.0646 of 5 stars$6.00+1.0%$38.67+544.4%-52.2%$380.30MN/A0.0061Analyst RevisionNews CoverageGap DownHigh Trading VolumeHUMAHumacyte2.1633 of 5 stars$3.01-1.0%$13.71+355.6%-34.9%$378.84M$1.57M-2.25150Analyst ForecastNews CoverageAURAAura Biosciences2.1433 of 5 stars$7.54+2.6%$23.00+205.0%-21.5%$376.63MN/A-4.3650Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeRAPPRapport Therapeutics1.7426 of 5 stars$10.18-3.1%$35.00+243.8%N/A$371.53MN/A-0.74N/AShort Interest ↑RNACCartesian Therapeutics2.5668 of 5 stars$14.44-8.6%$42.14+191.8%-20.5%$366.99M$47.94M-0.2764Positive NewsTSHATaysha Gene Therapies2.7686 of 5 stars$1.79+4.1%$6.63+270.1%-41.2%$366.95M$8.33M2.84180Positive NewsATXSAstria Therapeutics1.7878 of 5 stars$6.48+0.5%$26.67+311.5%-54.8%$365.69MN/A-3.1030HRTXHeron Therapeutics3.8932 of 5 stars$2.39+3.0%$5.67+137.1%-16.4%$364.07M$144.29M-13.28300Positive NewsBNTCBenitec Biopharma1.8966 of 5 stars$15.34+2.5%$24.43+59.2%+182.5%$359.74M$80,000.00-10.1620Analyst ForecastShort Interest ↑ Remove Ads Related Companies and Tools Related Companies Revance Therapeutics Competitors ABIVAX Société Anonyme Competitors Humacyte Competitors Aura Biosciences Competitors Rapport Therapeutics Competitors Cartesian Therapeutics Competitors Taysha Gene Therapies Competitors Astria Therapeutics Competitors Heron Therapeutics Competitors Benitec Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
